UK Markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
55.30+1.71 (+3.19%)
As of 4:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close53.59
Open54.00
Bid54.51 x 900
Ask55.33 x 1200
Day's range52.83 - 55.67
52-week range44.45 - 151.80
Volume358,552
Avg. volume728,361
Market cap10.298B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est72.64
  • EQS Group

    CureVac Streamlines European Network for mRNA Product Manufacturing

    DGAP-News: CureVac / Key word(s): Alliance14.09.2021 / 13:19 The issuer is solely responsible for the content of this announcement.CureVac Streamlines European Network for mRNA Product Manufacturing CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review with EMA Contracts with manufacturing partners WACKER and Celonic terminated; Rentschler Biopharma and Nov

  • Zacks

    Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study

    GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.

  • Motley Fool

    Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?

    CureVac (NASDAQ: CVAC) recently announced that Boehringer Ingelheim terminated a partnership on a messenger RNA lung cancer vaccine program. In this Motley Fool Live video recorded on Aug. 18, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not this canceled deal spells trouble for other mRNA cancer vaccines in development.